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CASE REPORT
Fulminant fatal cardiotoxicity following
cyclophosphamide therapy
Minako Katayama (MD)a,∗, Yukihiro Imai (MD)b, Hisako Hashimoto (MD)c,
Masayuki Kurata (MD)d, Kenichi Nagai (MD)c, Koichi Tamita (MD)e,
Shigefumi Morioka (MD, FJCC)e, Yutaka Furukawa (MD)e
a Department of Cardiology, Institute of Biomedical Research and Innovation, 2-2 Minatojima
Minamimachi Chuoku, Kobe 650-0047, Japan
b Department of Pathology, Kobe City Medical Center General Hospital, Kobe, Japan
c Department of Cell Therapy, Institute of Biomedical Research and Innovation, Kobe, Japan
d Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
e Department of Cardiology, Kobe City Medical Center General Hospital, Kobe, Japan
Received 30 October 2008; received in revised form 13 January 2009
Available online 20 February 2009
KEYWORDS
Pericarditis;
Complications;
Pathology
Summary A 59-year-old male with an abdominal mass that showed a diffuse
large B cell lymphoma underwent extirpation of the tumor and chemotherapy.
He subsequently received high-dose chemotherapy containing cyclophosphamide
(1.5 g/m2/day× 2 days), followed by autologous peripheral blood stem cell trans-
plantation. He developed congestive heart failure 5 days after administration of
cyclophosphamide. His electrocardiogram showed extremely low voltage with ST
segment change and echocardiogram showed diffusely increased left ventricular
wall thickness, an increase in myocardial echogenicity, pericardial effusion, and gen-
erally decreased systolic function. Congestive heart failure progressed rapidly and
he died the following day. Post-mortem examination of the heart revealed myocar-
dial hemorrhage, yellowish brown pericardial effusion, and ﬁbrinous pericarditis. His
liver was atrophic and focal necrosis was observed histologically. Cyclophosphamide-
induced cardiotoxicity occurred, even though the patient had both shown normal
cardiac function before high-dose chemotherapy and had received a lower dose of
cyclophosphamide. Concomitant administration of cytarabine might have affected
his liver function and there might have been interaction between the drugs.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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ntroduction
yclophosphamide-induced fatal cardiotoxicity
s a rare complication, occurring within 10 days
f receiving cyclophosphamide [1]. Although
ardiotoxicity is related to dosage, previous
nthracycline treatment, previous radiation, age
ver 50, and the presence of left ventricular (LV)
ysfunction, no deﬁnitive risk factors have yet
een identiﬁed [1,2]. We came across a case whose
linical course was rapidly progressive and fatal,
ven though he had presented with normal cardiac
unction before high-dose chemotherapy and sub-
equent peripheral blood stem cell transplantation
PBSCT).ase history
59-year-old male presented with an abdominal
ass, which showed a diffuse large B cell lym-
(
f
3
ig. 1 Electrocardiograms. (a) An electrocardiogram on adm
eveloped congestive heart failure. Extremely low voltage in331
homa. He underwent extirpation of the tumor and
hemotherapy.
Chemotherapy was performed with two courses
f cyclophosphamide, doxorubicin, vincristine
nd prednisolone, and 8 weeks’ treatment with
yclophosphamide, doxorubicin, methotrexate,
leomycin, vincristine, etoposide, ifosphamide,
nd prednisolone. As complete remission was
btained, high-dose chemotherapy with PBSCT was
nitiated. Peripheral blood stem cell harvest was
erformed using high-dose etoposide.
The total treatment dose of cyclophosphamide
nd doxorubicin received by the patient was
700mg/m2, and 400mg/m2, respectively. Elec-
rocardiogram was normal, and echocardiogram
ndicated normal LV systolic and diastolic function;
V ejection fraction (LVEF) was 58%, E/A = 0.96, and
he deceleration time of E wave was 245ms.
Priming for PBSCT comprised ranimustine
200mg/m2) for 2 days, carboplatin (300mg/m2)
or 4 days, and cytarabine (2 g/m2 × 2/day) for
days followed by 1.5 g/m2/day of cyclophos-
ission. (b) An electrocardiogram on the day the patient
limb leads and ST elevation in I, II,V3-6 were observed.
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cFig. 2 An echocardiogram showed a diffuse increase in le
and pericardial effusion.
phamide for 2 days. The patient developed general
fatigue after the initiation of cytarabine, with
signiﬁcant elevation of serum liver enzymes.
Creatine phosphokinase was elevated (220 IU/L)
on Day 7, the second day of high-dose cyclophos-
phamide therapy. Stem cells were reinfused on
Day 9. His urine volume decreased on Day 10,
and paroxysmal atrial ﬁbrillation was observed on
Day 11.
Physical examination on Day 11 revealed a blood
pressure of 110/80mmHg, an irregular heart rate of
110 beats/min, and a body temperature of 36.3 ◦C.
No cardiac murmur was present and inspiratory
crackles were detected by chest auscultation. The
jugular vein was dilated and peripheral edema was
observed. An electrocardiogram on that day showed
extremely low voltage in limb leads and ST ele-
vation in I, II,V3-6 (Fig. 1). An echocardiogram
showed diffusely increased LV wall thickness, and
myocardial echogenicity, pericardial effusion, and
generally impaired systolic function with a LVEF
35%. The diastolic thickness of interventricular sep-
tum and posterior LV wall was 1.4 cm and 1.5 cm,
respectively (Fig. 2).
p
a
h
pentricular wall thickness and in myocardial echogenicity,
The serum asparate aminotransferase concen-
ration was 350 IU/L (normal 3—40 IU/L), serum ala-
ine aminotransferase concentration was 106 IU/L
normal 8—40 IU/L), serum lactate dehydrogenase
as 5260 IU/L (normal 200—450 IU/L), serum cre-
tine phosphokinase (CK) was 938 IU/L (normal
5—130 IU/L) (MB 3%), and cardiac troponin T was
ositive.
A diagnosis of drug-induced myocarditis was sus-
ected and the patient was transferred to the
ntensive care unit. In spite of intensive support-
ve treatment with diuretics and catecholamines,
ow cardiac output aggravated renal function and
ontinuous hemodiaﬁltration was started. Percuta-
eous cardiopulmonary support was not applied to
he patient because of critical thrombocytopenia
nd neutropenia following high-dose chemother-
py. The patient deteriorated and irreversible
ardiac arrest occurred the following day (Day 12).
Post-mortem examination showed a ﬁbrinousericarditis with spotty pericardial hemorrhage and
yellowish brown pericardial effusion (120ml). The
eart weighed 430 g. The coronary arteries were
atent. Cut surface of the myocardium showed
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Fig. 3 Post-mortem examination showed ﬁbrinous pericarditis with spotty pericardial hemorrhage (a). The heart
weighed 430 g. Cut surface of the myocardium showed diffusely hemorrhagic muscle and bulging appearance of myocar-
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mial tissue (b). Histologically, there were interstitial ede
nﬂammatory cells nor lymphoma cells (c, d). Although f
he cardiac myocytes were histologically preserved.
iffusely hemorrhagic muscle and bulging appear-
nce of myocardial tissue. Histologically, there
ere interstitial edema and extravasation of ery-
hrocytes without inﬁltration of inﬂammatory cells
or lymphoma cells. Although foci of contraction
and necrosis were observed, most of the car-
iac myocytes were histologically preserved. There
as no myocyte hypertrophy or interstitial ﬁbro-
is (Fig. 3). The liver was atrophic and weighed
70 g. Focal necrosis was observed histologically,
nd there were no residual lymphoma cells.
iscussion
he number of therapeutic modalities available for
he treatment of neoplastic disease has increased
nd tremendous progress has been made in improv-
ng the morbidity and mortality from neoplastic
isease. However, life-threatening toxicities of
uch treatment remain a problem. It is therefore
t
i
p
mnd extravasation of erythrocytes without inﬁltration of
f contraction band necrosis were observed (e), most of
rucial to optimally manage comorbid illnesses and
ssociated toxicities, especially critical cardiotoxi-
ity.
Drug-related cardiac toxicity in patients treated
ith high-dose chemotherapy is an uncommon
ut potentially serious complication, and has
een associated mostly with cyclophosphamide-
ontaining regimens [1—3]. In the pathogenesis
f high-dose cyclophosphamide-associated cardiac
oxicity, toxic endothelial damage by cyclophos-
hamide causes extravasation of toxic metabolites
nd results in myocyte damage, interstitial hemor-
hage, and edema [1,2]. The incidence of fulminant
ongestive heart failure is reported to be 5—19%
1,4,5].
This patient’s clinical course and the post-
ortem pathological ﬁndings of his heart wereypical of cyclophosphamide-induced cardiotoxic-
ty. Although he was elderly and had received
revious anthracycline 400mg/m2, which is the
aximum dosage for the heart, LVEF and dias-
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tolic function of the heart were preserved before
high-dose chemotherapy for PBSCT. Single-agent
high-dose cyclophosphamide-associated cardiotox-
icity is dose dependent; however, the dose in the
present patient was 1.5 g/m2/day (46.5mg/kg) for
2 days, a level at which severe cardiotoxicity is not
common. On the other hand, cytarabine is asso-
ciated with cardiac arrhythmia and pericarditis.
The highest incidence and severity of cardiac toxi-
city have been reported when the two drugs were
coadministered [2]. In the present case, liver dys-
function, as a side effect of cytarabine, might have
affected the metabolism of cyclophosphamide, or
there might have been some interaction between
the drugs.
The occurrence of acute heart failure after
high-dose cyclophosphamide is difﬁcult to pre-
dict. Cardiac monitoring including electrocardio-
graphy and echocardiography are important in
the detection of clinical signs of cardiotoxicity.
Diffuse voltage loss as shown by electrocardio-
gram, increased LV wall thickness and generalized
increase in echogenicity by echocardiogram are
ﬁndings that indicate myocardial hemorrhage [1,6].
Echocardiographic ﬁgures of myocardial thicken-
ing of the LV wall are also observed in myocarditis
of any cause, inﬁltrative cardiomyopathy, hyper-
trophic cardiomyopathy, and also in cases of cardiac
invasion of malignant lymphoma [1,6,7]. Drug-
induced cardiotoxicity should therefore be taken
into consideration when using cyclophosphamide
therapy. Close communication between oncologists
and cardiologists is required because differential
diagnosis is difﬁcult in some situations.
[
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Recent studies have elucidated that cardiac
roponin I can be considered a sensitive and reli-
ble marker of acute minor myocardial damage in
atients undergoing high-dose chemotherapy [8]. It
ight be helpful to apply a rapid and high-sensitive
roponin test to cardiac monitoring for the early
etection of drug-induced cardiotoxicity.
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